Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

This study tests a new formulation of irinotecan (a chemotherapy drug) delivered in tiny fat-based particles called liposomes — given weekly — for patients with Ewing sarcoma (a bone and soft tissue cancer) that has come back or stopped responding to standard treatments. **You may be eligible if...** - You have been diagnosed with Ewing sarcoma, confirmed by biopsy and genetic testing - Your cancer has relapsed or is no longer responding to standard treatment - You have previously received standard Ewing sarcoma chemotherapy (doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide) - Your cancer is measurable on CT or MRI scans - Your overall health is good enough (ECOG 0–1) and organs are functioning adequately - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have active, uncontrolled brain or spinal cord metastases currently requiring steroids - Your prior treatment was completed less than 3 weeks ago (less than 2 weeks for radiation) - You have significant organ dysfunction that hasn't recovered Talk to your doctor to see if this trial is right for you.